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Abstract
Background: This study was undertaken to compare the in vitro effects of 17β-estradiol on
human epicardial coronary arteries, resistance coronary arteries and on arterial vessels usually
employed as grafts in surgical myocardial revascularization.
Methods: Coronary artery rings (descending coronary artery, right coronary artery, circumflex
coronary artery, first septal branch) and arterial graft rings (internal thoracic artery, gastro-
epiploic artery) obtained from human heart donors with heart not suitable to cardiac
transplantation were connected to force transducer for isometric force recording.
Precontracted specimens with and without endothelium were exposed to increasing
concentration of 17β-estradiol (3–30–300–3000 nmol/l) and to vehicle (0.1% v/v ethanol). We
also evaluated the effects of 17β-estradiol on vessels before and 20 minutes after exposure to
L-monomethyl-arginine and indomethacin.
Results:  17β-estradiol induced a significant relaxation in all precontracted vessels (mean
maximum effect: 78,6% ± 8,5). This effect was not different among the different rings and was
not related to the presence of endothelium. N-monomethyl-L-arginine and indomethacin did not
modify 17β-estradiol relaxant effect.
Conclusion:  The vasodilator action of the 17β-estradiol is similar on coronary arteries,
resistance coronary arteries and arterial vessels usually employed as grafts in myocardial
revascularization.
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Background
The interest for 17β-estradiol as vasoactive and vasopro-
tective agent is raising, since it was observed that it takes
effect directly on the vascular wall, improving vasodilata-
tion and inhibiting neointimal proliferation [1-7]. New
devices, such as 17β-estradiol-eluting- stents, were devel-
oped to protect revascularized heart [8], hypothesizing a
new role of 17β-estradiol for tertiary prevention in coro-
nary artery disease (CAD).
Coronary perfusion after coronary artery bypass grafting
(CABG) is a complex system dependent on several factors,
including gender and the type of grafts employed [9-14].
Women have smaller coronary arteries than men and it
can lead to incomplete revascularization and increased
risk of in-hospital mortality [10]. The type of graft
employed can affect outcomes as arterial grafts permit
superior long-term patency and lower mortality rate [11-
14]. Moreover, blood flow distribution in cardiac wall is
related to not only diastolic pressure and section area of
epicardial vessels but also depends on the resistance to the
blood flow determined by intramyocardial branches, i.e.
first septal branch [15].
The effect of estrogen on coronary system after surgical
myocardial revascularization should be evaluated consid-
ering together all vessels that permit blood circulation,
including grafts, epicardial coronary arteries and resist-
ance vessels. To date, a comprehensive evaluation of estro-
genic action on coronary arteries system was not
performed. This study was undertaken to compare the
effect of 17β-estradiol on epicardial coronary arteries,
resistance coronary vessels and arteries employed as grafts
in CABG.
Methods
We evaluated the in vitro effect of 17β-estradiol on human
epicardial coronary arteries (anterior interventricular
artery, right coronary artery, circumflex artery) resistance
vessels (first septal branch) and arteries usually employed
in CABG (left internal mammary artery, gastroepiploic
artery).
The vessels were obtained from 11 human donors whose
heart was not suitable for cardiac transplantation and was
harvested for banking cryopreserved valvular homografts.
All patients were female (mean age 38 ± 11 years, range
18–54 years). All women had normal coronary arteries,
without macroscopic atherosclerotic process.
Coronaries were dissected within 1 hours after the
removal of heart and all segments were immediately put
in a modified Krebs solution (composition in mmol/l:
NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25, EDTA Calcium 0.026, glucose 11.1, albumin
0.1) at 4°C to be conserved. At the time of experiment, at
maximum 1 hour after dissection, the vessels were cut into
3–4 mm long rings and suspended in an organ bath con-
taining 10 ml modified Krebs solution aerated constantly
with 95% O2 and 5% CO2 and maintained at 37°C. Each
ring was mounted on a triangular-shaped metal hook con-
nected to force transducer for isometric force recordings.
Resting force was 2 grams [16].
Each single experiment was conducted on two rings from
the same vessel. In one ring endothelium was mechani-
cally removed with a wooden applicator (Group 1) in
order to simulate an atheromasic vessel. The ring was pre-
contracted with prostaglandin F2α (PGF2α, 1 µmol/l), then
histamine (0.1 µmol/l) was added and the absence of
vasodilative effect confirmed the complete removal of the
endothelium (Figure 1-A). In the other ring from the same
vessel, endothelium was preserved (Group 2). It was pre-
contracted with prostaglandin F2α (PGF2α, 1 µmol/l) and
exposed to the same concentration of histamine (0.1
µmol/l) with subsequent complete vasodilatation (Figure
2-B).
The rings (Group1 and Group2) were washed out and pre-
contracted with prostaglandin F2α (PGF2α, 1 µmol/l). After
the contraction plateau was reached (about 10 minutes),
rings were exposed to the vehicle (0.1% v/v ethanol, Fig-
ure 1-C). The bath solution was replaced, the rings were
precontracted again with prostaglandin F2α  (PGF2α, 1
µmol/l) and, at the contraction plateau, they were
exposed to increasing concentrations of 17β-estradiol (3–
30–300–3000 nmol/l, Figure 1D).
At the end of the experiment, the rings were washed out
and we evaluated the effects of increasing concentrations
of 17β-estradiol after the exposition to L-monomethyl-
arginine (L-NMMA, 0.1 mmol/l) and indomethacin (10
µmol/l), L-NMMA is a non-specific inhibitor of nitric
oxide synthase (NOS) that permits to evaluate the role of
nitric oxide (NO) in vasoactive action of estrogen.
Indomethacin is a cyclo-oxygenase inhibitor that blocks
endothelial synthesis of prostacyclin. The rings were pre-
treated with both L-NMMA and indomethacin together
for 20 minutes and precontracted with prostaglandin F2α
(PGF2α, 1 µmol/l). After the contraction plateau was
reached (about 10 minutes), rings were exposed to
increasing concentrations of 17β-estradiol (3–30–300–
3000 nmol/l).
This study had the approval of our Institutional Ethics
Committee.
Statistical analysis
The effect of 17β-estradiol on vessels was expressed as the
percentage relaxation of the maximum contractionJournal of Cardiothoracic Surgery 2006, 1:46 http://www.cardiothoracicsurgery.org/content/1/1/46
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A recording showing the relaxant effect of 17β-estradiol on human female coronary arteries Figure 1
A recording showing the relaxant effect of 17β-estradiol on human female coronary arteries. In panel A, histamine had no 
effects on a denuded ring. In panel B, endothelium was preserved and histamine had a relaxant effect. In panel C, a ring was 
precontracted with PGF2α and exposed to the solvent (ethanol), without vasorelaxation. Adding 3 µM of 17β-estradiol to the 
organ bath with ethanol, the force transducer recorded the maximum decrease in force within 10 minutes. Panel D shows the 
dose-dependent relaxation of a precontracted ring exposed to increasing concentrations of 17β-estradiol (3–30–300–3000 
nmol/l).Journal of Cardiothoracic Surgery 2006, 1:46 http://www.cardiothoracicsurgery.org/content/1/1/46
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induced by PGF2α. Continuous variables were expressed
as mean ± standard deviation of the mean (SD). Differ-
ences between two groups were evaluated using Student's
t-test. Repeated-measures analysis of variance (ANOVA)
was used to compare more than two means. If statistically
significant, Student's paired t test was then performed,
with Bonferroni's method used to correct for multiple
comparisons. A p value of less than 0.05 was considered
statistically significant. Statistical analyses were performed
using SPSS 13.0 software (SPSS, Inc, Chicago, IL).
Results
17β-estradiol induced significant relaxation of precon-
tracted coronary artery segments and vessels employed in
CABG (compared with vehicle solvent, p < 0.05, data not
shown). This vascular response to 17β-estradiol was con-
centration-dependent with a maximum effect at 3 µmol/l-
dose (mean maximum effect: 78.6% ± 8.5%).
There were no significant differences in vasorelaxation
between different types of vessels (p > 0.05, n = 22 in each
group; Figure 2). It suggests that estrogen effect on vascu-
lar system is not dependent on vascular district and on
segment's size.
The relaxant effect of estrogen was similar in groups with
and without endothelium (p > 0.05, n = 66 in each group,
Figure 3), suggesting an endothelium-independent mech-
anism of action. L-NMMA and indomethacin did not sig-
nificantly inhibit the relaxation produced by increasing
concentrations of 17β-estradiol (Figure 4), excluding a
role of nitric oxide and prostacyclin on estrogen-depend-
ent relaxation.
Discussion
The relationship between 17β-estradiol and heart has
been widely evaluated in the last decade, since it was
observed that the risk of coronary artery disease signifi-
cantly increases in women after menopause [17]. Several
clinical studies focused on the protective role of postmen-
opausal HRT with contrasting results that leave the debate
opened [18,19]. We shifted the attention on tertiary pre-
The effect of increasing concentrations (3–30–300–3000  nmol/l) of 17β-estradiol on vessels with and without  endothelium Figure 3
The effect of increasing concentrations (3–30–300–3000 
nmol/l) of 17β-estradiol on vessels with and without 
endothelium. The relaxation is expressed as the percentage 
of the maximum effect obtained with PGF2α. The peak ten-
sion with PGF2α was 3.2 ± 1.3 for intact vessels and 3.4 ± 1.0 
for denuded vessels. There were no significant differences in 
vascular response to estrogen in groups with or without 
endothelium at each estrogen concentration (n = 66 for 
group with endothelium, n = 66 for group without endothe-
lium, p > 0.05).
The effects of 17β-estradiol on different vessels with and  without endothelium Figure 2
The effects of 17β-estradiol on different vessels with and 
without endothelium. The effect of 17β-estradiol on vessels 
is expressed as the percentage relaxation of the maximum 
contraction induced by PGF2α. The relaxant effect of 17β-
estradiol at each dose was similar in all groups (n = 22 for 
each group, p > 0.05 by repeated-measures analysis of vari-
ance). No intra-group significant difference was found 
between the same vessels with and without endothelium 
(data not shown). 17β-estradiol has a similar vasoactive effect 
on both epicardial coronaries and septal branch and arteries 
usually used as graft in myocardial revascularization at each 
concentration.Journal of Cardiothoracic Surgery 2006, 1:46 http://www.cardiothoracicsurgery.org/content/1/1/46
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vention of CAD to understand the vasoactive effects of
17β-estradiol on all conduits of the revascularized heart.
Our main question regarded the eventual diverse effects of
estrogen on resistance vessel, epicardial vessels and arter-
ies commonly employed as graft in CABG. Several studies
evaluated only epicardial vessels [16,20-23], without con-
sidering the importance of resistance vessels on heart per-
fusion. Moreover, LIMA graft was found responsible to
estrogen but no comparison with coronaries was per-
formed [24]. This study demonstrated a global acute
vasorelaxant response of all vessels to 17β-estradiol which
ameliorates all the complex physiology of blood flow in
heart and arterial grafts. Hence, estrogen can acutely
increase myocardial perfusion in women after coronary
artery bypass grafting, acting through both a vasodilata-
tion of coronary epicardial vessels and grafts and a
decrease in resistance offered by resistance vessels.
The estrogenic vasoactive effect was found similar on nor-
mal and endothelium-deprived segments, confirming
previous data on epicardial vessels [16,22,23]. Impaired-
endothelium is characteristic of atherosclerotic coronaries
and diseased arterial grafts. Surgical maneuvers are dem-
onstrated to impair graft's endothelium and coronaries at
incision site, worsening the endothelial function and
leading to the well-known graft disease. The endothelium-
independent vasorelaxation can be helpful in preventing
perioperative vasoconstriction due to impaired endothe-
lium and arterial graft spasm [23,24]. Moreover, estrogens
accelerate endothelial cells growth, increasing local
expression of vascular endothelial growth factors and
inhibiting endothelial cells apoptosis [25]. This estrogen-
related rapid reendothelialization, as well as vasorelaxa-
tion and inhibition of neointimal proliferation, led to the
development of new estrogen-eluting stents [8] and can
also represent protective effects for surgical revascularized
heart. It could be useful especially in female sex, in which
perioperative and postoperative complications are
increased by an unfavorable anatomy [9,10].
The vasorelaxant mechanisms of 17β-estradiol on vascu-
lar conduits are far to be completely clarified [26]. New
data about non-genomic mechanisms of action lead to
consider 17β-estradiol also as an acute and mid-term
vasodilator. 17β-estradiol both stimulates endothelial
NO production in a non-genomic manner and has vasore-
laxant effects on impaired vessels acting on the muscular
layer through an endothelium-independent mechanism.
Smooth muscular cells respond to estrogens stimulating
myocyte NO-synthesis or through similar Ca-antagonist
mechanisms [16,23,27,28]. Our study confirms the simi-
lar Ca-antagonist mechanism, as L-NMMA (N-monome-
thyl-L-arginine) does not change vascular response, even
if we did not evaluate the myocyte NO-synthesis.
Limitations of the study
This study was performed on in vitro specimens and the
concomitant in vivo effects could not be evaluated. By its
nature, it did not considered chronic estrogenic effects
that can be related to different mechanisms, such as
genomic induction. Moreover, we focused the attention
on endothelium-independent mechanisms similar to Ca-
antagonist, as they are responsible of vasodilatation on
both normal and impaired vessels, which are characteris-
tic of revascularized heart.
Conclusion
This study demonstrated that 17β-estradiol has a similar
relaxant effect on human female coronary arteries (epicar-
dial capacitance arteries and resistance vessels) and arter-
ies used as graft in CABG. Acute estrogenic administration
can have vasorelaxant effect on all female revascularized
The effect of L-NMMA (0.1 mmol/l) and indomethacin (10  µmol/l) on 17β-estradiol vasorelaxation Figure 4
The effect of L-NMMA (0.1 mmol/l) and indomethacin (10 
µmol/l) on 17β-estradiol vasorelaxation. The relaxation is 
expressed as the percentage of the maximum effect obtained 
with PGF2α. The peak tension with PGF2α was 3.3 ± 0.9 for 
experiment before exposure to L-NMMA and indomethacin 
and 3.1 ± 1.2 for the experiments after exposure to L-
NMMA and indomethacin. We did not find significant differ-
ences among groups at each 17β-estradiol concentration (n 
= 132 in each group, p > 0.05). No intra-group significant dif-
ference was found between different vessels and between 
vessels with and without endothelium (p > 0.05, data not 
shown).Journal of Cardiothoracic Surgery 2006, 1:46 http://www.cardiothoracicsurgery.org/content/1/1/46
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heart, thus protecting coronaries and grafts and favoring
reendothelialization.
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CABG coronary artery bypass grafting
CAD coronary artery disease
HRT hormone replacement therapy
L-NMMA L-monomethyl-arginine
LIMA left internal mammary artery
NO nitric oxide
NOS nitric oxide synthase
PGF2α, prostaglandin F2α
SD standard deviation of the mean
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